nodes	percent_of_prediction	percent_of_DWPC	metapath
Bisacodyl—GPR55—adrenal gland—breast cancer	0.0405	0.405	CbGeAlD
Bisacodyl—GPR55—endocrine gland—breast cancer	0.0352	0.352	CbGeAlD
Bisacodyl—GPR55—lymph node—breast cancer	0.0243	0.243	CbGeAlD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CCL27—breast cancer	0.00557	0.0153	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CXCL3—breast cancer	0.00557	0.0153	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—GPER1—breast cancer	0.00534	0.0146	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—NMBR—breast cancer	0.00512	0.014	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—CCL20—breast cancer	0.00506	0.0139	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—LPAR1—breast cancer	0.0049	0.0134	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—PTGER1—breast cancer	0.00476	0.013	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—CNR2—breast cancer	0.00451	0.0124	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—WNT10B—breast cancer	0.00435	0.0119	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CCL27—breast cancer	0.00424	0.0116	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CXCL3—breast cancer	0.00424	0.0116	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CCL20—breast cancer	0.00403	0.011	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—LPAR1—breast cancer	0.0039	0.0107	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—CXCL2—breast cancer	0.00388	0.0106	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—AGTR2—breast cancer	0.00388	0.0106	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CNR2—breast cancer	0.00359	0.00984	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—CXCR4—breast cancer	0.0033	0.00905	CbGpPWpGaD
Bisacodyl—GPR55—G alpha (i) signalling events—CXCL12—breast cancer	0.0033	0.00905	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CXCL2—breast cancer	0.00309	0.00846	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—AGTR2—breast cancer	0.00309	0.00846	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CCL20—breast cancer	0.00307	0.00841	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—GPER1—breast cancer	0.00302	0.00827	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—LPAR1—breast cancer	0.00297	0.00814	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—EDNRB—breast cancer	0.00295	0.0081	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—STARD8—breast cancer	0.00295	0.0081	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—NMBR—breast cancer	0.00289	0.00793	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—GPER1—breast cancer	0.00274	0.00751	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CNR2—breast cancer	0.00273	0.00749	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—PTGER1—breast cancer	0.00269	0.00737	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—NMBR—breast cancer	0.00263	0.0072	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CXCL12—breast cancer	0.00262	0.00719	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CXCR4—breast cancer	0.00262	0.00719	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—WNT1—breast cancer	0.00257	0.00704	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PTGER1—breast cancer	0.00244	0.0067	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—PDE2A—breast cancer	0.0024	0.00657	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—CCL27—breast cancer	0.0024	0.00657	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—CXCL3—breast cancer	0.0024	0.00657	CbGpPWpGaD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—AGTR1—breast cancer	0.00237	0.00651	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CXCL2—breast cancer	0.00235	0.00644	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—AGTR2—breast cancer	0.00235	0.00644	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—PTHLH—breast cancer	0.00232	0.00637	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—EDNRB—breast cancer	0.00225	0.00617	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—WNT10B—breast cancer	0.00223	0.00612	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PDE2A—breast cancer	0.00218	0.00597	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—CCL27—breast cancer	0.00218	0.00597	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—CXCL3—breast cancer	0.00218	0.00597	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CALCA—breast cancer	0.00205	0.00561	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CXCR4—breast cancer	0.002	0.00548	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CXCL12—breast cancer	0.002	0.00548	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—AGTR1—breast cancer	0.00181	0.00495	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—RGS2—breast cancer	0.00175	0.0048	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—CCL20—breast cancer	0.00173	0.00475	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—LGR6—breast cancer	0.0017	0.00465	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CCDC88C—breast cancer	0.0017	0.00465	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—LPAR1—breast cancer	0.00168	0.0046	CbGpPWpGaD
Bisacodyl—Abdominal pain—Idarubicin—breast cancer	0.00166	0.00312	CcSEcCtD
Bisacodyl—Abdominal pain—Raloxifene—breast cancer	0.00166	0.00312	CcSEcCtD
Bisacodyl—Dehydration—Paclitaxel—breast cancer	0.00165	0.0031	CcSEcCtD
Bisacodyl—Immune system disorder—Vinorelbine—breast cancer	0.00165	0.0031	CcSEcCtD
Bisacodyl—Dizziness—Exemestane—breast cancer	0.00165	0.0031	CcSEcCtD
Bisacodyl—Hypersensitivity—Anastrozole—breast cancer	0.00163	0.00307	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—SFRP1—breast cancer	0.00162	0.00444	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—GPER1—breast cancer	0.00162	0.00444	CbGpPWpGaD
Bisacodyl—Diarrhoea—Ixabepilone—breast cancer	0.00161	0.00303	CcSEcCtD
Bisacodyl—Cramp muscle—Paclitaxel—breast cancer	0.0016	0.003	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—RGS2—breast cancer	0.00159	0.00436	CbGpPWpGaD
Bisacodyl—Malnutrition—Vinorelbine—breast cancer	0.00159	0.00299	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—PDE4D—breast cancer	0.00158	0.00435	CbGpPWpGaD
Bisacodyl—Vomiting—Exemestane—breast cancer	0.00158	0.00298	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—CCL20—breast cancer	0.00157	0.00431	CbGpPWpGaD
Bisacodyl—Immune system disorder—Thiotepa—breast cancer	0.00157	0.00296	CcSEcCtD
Bisacodyl—Headache—Exemestane—breast cancer	0.00156	0.00294	CcSEcCtD
Bisacodyl—Dizziness—Ixabepilone—breast cancer	0.00155	0.00292	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—NMBR—breast cancer	0.00155	0.00425	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Idarubicin—breast cancer	0.00155	0.00291	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—CNR2—breast cancer	0.00154	0.00423	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—LPAR1—breast cancer	0.00152	0.00418	CbGpPWpGaD
Bisacodyl—Malnutrition—Thiotepa—breast cancer	0.00152	0.00285	CcSEcCtD
Bisacodyl—Diarrhoea—Letrozole—breast cancer	0.00151	0.00285	CcSEcCtD
Bisacodyl—Diarrhoea—Anastrozole—breast cancer	0.00151	0.00285	CcSEcCtD
Bisacodyl—Vomiting—Ixabepilone—breast cancer	0.00149	0.00281	CcSEcCtD
Bisacodyl—Anaphylactic shock—Melphalan—breast cancer	0.00148	0.00279	CcSEcCtD
Bisacodyl—Nausea—Exemestane—breast cancer	0.00148	0.00278	CcSEcCtD
Bisacodyl—Headache—Ixabepilone—breast cancer	0.00147	0.00277	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Chlorambucil—breast cancer	0.00147	0.00276	CcSEcCtD
Bisacodyl—Dizziness—Anastrozole—breast cancer	0.00146	0.00275	CcSEcCtD
Bisacodyl—Dizziness—Letrozole—breast cancer	0.00146	0.00275	CcSEcCtD
Bisacodyl—Angioedema—Vinorelbine—breast cancer	0.00145	0.00273	CcSEcCtD
Bisacodyl—Anaphylactic shock—Goserelin—breast cancer	0.00145	0.00272	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CUL5—breast cancer	0.00144	0.00396	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—HEYL—breast cancer	0.00144	0.00396	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PTGER1—breast cancer	0.00144	0.00396	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PDE4D—breast cancer	0.00144	0.00395	CbGpPWpGaD
Bisacodyl—Diarrhoea—Raloxifene—breast cancer	0.00144	0.0027	CcSEcCtD
Bisacodyl—Diarrhoea—Idarubicin—breast cancer	0.00144	0.0027	CcSEcCtD
Bisacodyl—Shock—Goserelin—breast cancer	0.00142	0.00268	CcSEcCtD
Bisacodyl—Nervous system disorder—Goserelin—breast cancer	0.00142	0.00267	CcSEcCtD
Bisacodyl—Vomiting—Anastrozole—breast cancer	0.00141	0.00265	CcSEcCtD
Bisacodyl—Vomiting—Letrozole—breast cancer	0.00141	0.00265	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—CNR2—breast cancer	0.0014	0.00385	CbGpPWpGaD
Bisacodyl—Dehydration—Docetaxel—breast cancer	0.0014	0.00263	CcSEcCtD
Bisacodyl—Nausea—Ixabepilone—breast cancer	0.0014	0.00263	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Chlorambucil—breast cancer	0.00139	0.00262	CcSEcCtD
Bisacodyl—Dizziness—Raloxifene—breast cancer	0.00139	0.00261	CcSEcCtD
Bisacodyl—Headache—Letrozole—breast cancer	0.00139	0.00261	CcSEcCtD
Bisacodyl—Headache—Anastrozole—breast cancer	0.00139	0.00261	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—CXCL8—breast cancer	0.00137	0.00375	CbGpPWpGaD
Bisacodyl—Immune system disorder—Irinotecan—breast cancer	0.00136	0.00256	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—RSPO3—breast cancer	0.00136	0.00372	CbGpPWpGaD
Bisacodyl—Cramp muscle—Docetaxel—breast cancer	0.00135	0.00255	CcSEcCtD
Bisacodyl—Dehydration—Capecitabine—breast cancer	0.00135	0.00255	CcSEcCtD
Bisacodyl—Abdominal pain—Chlorambucil—breast cancer	0.00134	0.00253	CcSEcCtD
Bisacodyl—Colitis—Epirubicin—breast cancer	0.00134	0.00252	CcSEcCtD
Bisacodyl—Vomiting—Idarubicin—breast cancer	0.00133	0.00251	CcSEcCtD
Bisacodyl—Vomiting—Raloxifene—breast cancer	0.00133	0.00251	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—AGTR2—breast cancer	0.00133	0.00364	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—CXCL2—breast cancer	0.00133	0.00364	CbGpPWpGaD
Bisacodyl—Immune system disorder—Gemcitabine—breast cancer	0.00132	0.00249	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—WNT10B—breast cancer	0.00132	0.00362	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—WWOX—breast cancer	0.00132	0.00362	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—WNT1—breast cancer	0.00132	0.00362	CbGpPWpGaD
Bisacodyl—Headache—Raloxifene—breast cancer	0.00132	0.00248	CcSEcCtD
Bisacodyl—Headache—Idarubicin—breast cancer	0.00132	0.00248	CcSEcCtD
Bisacodyl—Nausea—Anastrozole—breast cancer	0.00131	0.00247	CcSEcCtD
Bisacodyl—Nausea—Letrozole—breast cancer	0.00131	0.00247	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—PTHLH—breast cancer	0.00131	0.0036	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Tamoxifen—breast cancer	0.00131	0.00246	CcSEcCtD
Bisacodyl—Anaphylactic shock—Vinorelbine—breast cancer	0.0013	0.00244	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CXCL3—breast cancer	0.00129	0.00353	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PDE2A—breast cancer	0.00129	0.00353	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—INHBB—breast cancer	0.00129	0.00353	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CCL27—breast cancer	0.00129	0.00353	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Melphalan—breast cancer	0.00128	0.00241	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Vinblastine—breast cancer	0.00127	0.0024	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—EDNRB—breast cancer	0.00127	0.00349	CbGpPWpGaD
Bisacodyl—Nervous system disorder—Vinorelbine—breast cancer	0.00127	0.00239	CcSEcCtD
Bisacodyl—Muscle spasms—Irinotecan—breast cancer	0.00126	0.00237	CcSEcCtD
Bisacodyl—Hypersensitivity—Chlorambucil—breast cancer	0.00125	0.00236	CcSEcCtD
Bisacodyl—Nausea—Raloxifene—breast cancer	0.00125	0.00235	CcSEcCtD
Bisacodyl—Nausea—Idarubicin—breast cancer	0.00125	0.00235	CcSEcCtD
Bisacodyl—Colitis—Doxorubicin—breast cancer	0.00124	0.00233	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Tamoxifen—breast cancer	0.00124	0.00233	CcSEcCtD
Bisacodyl—Abdominal pain—Vinblastine—breast cancer	0.00123	0.00232	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—DLL4—breast cancer	0.00123	0.00336	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—BMPR2—breast cancer	0.00123	0.00336	CbGpPWpGaD
Bisacodyl—Nervous system disorder—Thiotepa—breast cancer	0.00121	0.00228	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—AGTR2—breast cancer	0.00121	0.00331	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—CXCL2—breast cancer	0.00121	0.00331	CbGpPWpGaD
Bisacodyl—Abdominal discomfort—Capecitabine—breast cancer	0.00121	0.00227	CcSEcCtD
Bisacodyl—Abdominal pain—Tamoxifen—breast cancer	0.0012	0.00225	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—PTHLH—breast cancer	0.00119	0.00327	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Goserelin—breast cancer	0.00118	0.00223	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CDH5—breast cancer	0.00118	0.00322	CbGpPWpGaD
Bisacodyl—Syncope—Irinotecan—breast cancer	0.00117	0.00221	CcSEcCtD
Bisacodyl—Diarrhoea—Chlorambucil—breast cancer	0.00116	0.00219	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—CALCA—breast cancer	0.00116	0.00317	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—EDNRB—breast cancer	0.00115	0.00317	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—SFRP2—breast cancer	0.00115	0.00316	CbGpPWpGaD
Bisacodyl—Loss of consciousness—Irinotecan—breast cancer	0.00115	0.00216	CcSEcCtD
Bisacodyl—Hypersensitivity—Vinblastine—breast cancer	0.00115	0.00216	CcSEcCtD
Bisacodyl—Abdominal pain—Goserelin—breast cancer	0.00114	0.00215	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PRLR—breast cancer	0.00113	0.0031	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—CXCL12—breast cancer	0.00113	0.0031	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—CXCR4—breast cancer	0.00113	0.0031	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Vinorelbine—breast cancer	0.00112	0.0021	CcSEcCtD
Bisacodyl—Hypersensitivity—Tamoxifen—breast cancer	0.00112	0.0021	CcSEcCtD
Bisacodyl—Immune system disorder—Paclitaxel—breast cancer	0.00111	0.00208	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—GLI2—breast cancer	0.00109	0.003	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—VCP—breast cancer	0.00109	0.003	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Melphalan—breast cancer	0.00109	0.00206	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CXCL8—breast cancer	0.00109	0.00298	CbGpPWpGaD
Bisacodyl—Vomiting—Chlorambucil—breast cancer	0.00108	0.00203	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—LEPR—breast cancer	0.00108	0.00295	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Irinotecan—breast cancer	0.00107	0.00201	CcSEcCtD
Bisacodyl—Anaphylactic shock—Mitoxantrone—breast cancer	0.00107	0.00201	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Thiotepa—breast cancer	0.00107	0.00201	CcSEcCtD
Bisacodyl—Malnutrition—Paclitaxel—breast cancer	0.00107	0.00201	CcSEcCtD
Bisacodyl—Diarrhoea—Vinblastine—breast cancer	0.00107	0.00201	CcSEcCtD
Bisacodyl—Hypersensitivity—Goserelin—breast cancer	0.00107	0.00201	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Vinorelbine—breast cancer	0.00106	0.00199	CcSEcCtD
Bisacodyl—Shock—Mitoxantrone—breast cancer	0.00105	0.00198	CcSEcCtD
Bisacodyl—Shock—Irinotecan—breast cancer	0.00105	0.00198	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—CALCA—breast cancer	0.00105	0.00288	CbGpPWpGaD
Bisacodyl—Nervous system disorder—Irinotecan—breast cancer	0.00105	0.00197	CcSEcCtD
Bisacodyl—Anaphylactic shock—Gemcitabine—breast cancer	0.00104	0.00196	CcSEcCtD
Bisacodyl—Diarrhoea—Tamoxifen—breast cancer	0.00104	0.00195	CcSEcCtD
Bisacodyl—Dizziness—Vinblastine—breast cancer	0.00103	0.00194	CcSEcCtD
Bisacodyl—Muscle spasms—Paclitaxel—breast cancer	0.00103	0.00193	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—CXCR4—breast cancer	0.00103	0.00281	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—CXCL12—breast cancer	0.00103	0.00281	CbGpPWpGaD
Bisacodyl—Abdominal pain—Vinorelbine—breast cancer	0.00102	0.00193	CcSEcCtD
Bisacodyl—Anaphylactic shock—Fluorouracil—breast cancer	0.00102	0.00193	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—AGTR1—breast cancer	0.00102	0.0028	CbGpPWpGaD
Bisacodyl—Nervous system disorder—Gemcitabine—breast cancer	0.00102	0.00192	CcSEcCtD
Bisacodyl—Diarrhoea—Melphalan—breast cancer	0.00101	0.00191	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Thiotepa—breast cancer	0.00101	0.0019	CcSEcCtD
Bisacodyl—Nausea—Chlorambucil—breast cancer	0.00101	0.0019	CcSEcCtD
Bisacodyl—Nervous system disorder—Fluorouracil—breast cancer	0.001	0.00189	CcSEcCtD
Bisacodyl—Dizziness—Tamoxifen—breast cancer	0.001	0.00188	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—ARHGDIA—breast cancer	0.001	0.00274	CbGpPWpGaD
Bisacodyl—Vomiting—Vinblastine—breast cancer	0.000991	0.00186	CcSEcCtD
Bisacodyl—Diarrhoea—Goserelin—breast cancer	0.000989	0.00186	CcSEcCtD
Bisacodyl—Abdominal pain—Thiotepa—breast cancer	0.000978	0.00184	CcSEcCtD
Bisacodyl—Headache—Vinblastine—breast cancer	0.000976	0.00184	CcSEcCtD
Bisacodyl—Angioedema—Paclitaxel—breast cancer	0.000975	0.00184	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—FST—breast cancer	0.000974	0.00267	CbGpPWpGaD
Bisacodyl—Vomiting—Tamoxifen—breast cancer	0.000963	0.00181	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—HEY2—breast cancer	0.000962	0.00264	CbGpPWpGaD
Bisacodyl—Syncope—Paclitaxel—breast cancer	0.000957	0.0018	CcSEcCtD
Bisacodyl—Dizziness—Goserelin—breast cancer	0.000956	0.0018	CcSEcCtD
Bisacodyl—Hypersensitivity—Vinorelbine—breast cancer	0.000954	0.0018	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—RPS6KB2—breast cancer	0.000951	0.00261	CbGpPWpGaD
Bisacodyl—Headache—Tamoxifen—breast cancer	0.000948	0.00178	CcSEcCtD
Bisacodyl—Vomiting—Melphalan—breast cancer	0.000942	0.00177	CcSEcCtD
Bisacodyl—Dehydration—Epirubicin—breast cancer	0.000942	0.00177	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—RGS2—breast cancer	0.00094	0.00258	CbGpPWpGaD
Bisacodyl—Immune system disorder—Docetaxel—breast cancer	0.000939	0.00177	CcSEcCtD
Bisacodyl—Loss of consciousness—Paclitaxel—breast cancer	0.000938	0.00177	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CCL20—breast cancer	0.000929	0.00255	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—AGTR1—breast cancer	0.000927	0.00254	CbGpPWpGaD
Bisacodyl—Nausea—Vinblastine—breast cancer	0.000926	0.00174	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Irinotecan—breast cancer	0.000922	0.00174	CcSEcCtD
Bisacodyl—Vomiting—Goserelin—breast cancer	0.000919	0.00173	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—ITPR1—breast cancer	0.000916	0.00251	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Thiotepa—breast cancer	0.000911	0.00171	CcSEcCtD
Bisacodyl—Immune system disorder—Capecitabine—breast cancer	0.000909	0.00171	CcSEcCtD
Bisacodyl—Headache—Goserelin—breast cancer	0.000906	0.0017	CcSEcCtD
Bisacodyl—Malnutrition—Docetaxel—breast cancer	0.000905	0.0017	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—TLE3—breast cancer	0.0009	0.00247	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—LPAR1—breast cancer	0.0009	0.00247	CbGpPWpGaD
Bisacodyl—Nausea—Tamoxifen—breast cancer	0.000899	0.00169	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Gemcitabine—breast cancer	0.000898	0.00169	CcSEcCtD
Bisacodyl—Abdominal discomfort—Methotrexate—breast cancer	0.000897	0.00169	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—HEY1—breast cancer	0.000891	0.00244	CbGpPWpGaD
Bisacodyl—Diarrhoea—Vinorelbine—breast cancer	0.000886	0.00167	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Fluorouracil—breast cancer	0.000883	0.00166	CcSEcCtD
Bisacodyl—Nausea—Melphalan—breast cancer	0.00088	0.00166	CcSEcCtD
Bisacodyl—Malnutrition—Capecitabine—breast cancer	0.000876	0.00165	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—DLL1—breast cancer	0.000874	0.0024	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Mitoxantrone—breast cancer	0.000873	0.00164	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Irinotecan—breast cancer	0.000873	0.00164	CcSEcCtD
Bisacodyl—Dehydration—Doxorubicin—breast cancer	0.000872	0.00164	CcSEcCtD
Bisacodyl—Anaphylactic shock—Paclitaxel—breast cancer	0.000871	0.00164	CcSEcCtD
Bisacodyl—Muscle spasms—Docetaxel—breast cancer	0.00087	0.00164	CcSEcCtD
Bisacodyl—Nausea—Goserelin—breast cancer	0.000859	0.00162	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—HIST1H2BK—breast cancer	0.000858	0.00235	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—HIST1H2BC—breast cancer	0.000858	0.00235	CbGpPWpGaD
Bisacodyl—Shock—Paclitaxel—breast cancer	0.000857	0.00161	CcSEcCtD
Bisacodyl—Dizziness—Vinorelbine—breast cancer	0.000856	0.00161	CcSEcCtD
Bisacodyl—Nervous system disorder—Paclitaxel—breast cancer	0.000854	0.00161	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—GRB7—breast cancer	0.00085	0.00233	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PDE4D—breast cancer	0.00085	0.00233	CbGpPWpGaD
Bisacodyl—Diarrhoea—Thiotepa—breast cancer	0.000846	0.00159	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—CSF2—breast cancer	0.000846	0.00232	CbGpPWpGaD
Bisacodyl—Abdominal pain—Irinotecan—breast cancer	0.000844	0.00159	CcSEcCtD
Bisacodyl—Abdominal pain—Mitoxantrone—breast cancer	0.000844	0.00159	CcSEcCtD
Bisacodyl—Muscle spasms—Capecitabine—breast cancer	0.000842	0.00158	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—TAB2—breast cancer	0.000835	0.00229	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—ITPR1—breast cancer	0.000832	0.00228	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CNR2—breast cancer	0.000828	0.00227	CbGpPWpGaD
Bisacodyl—GPR55—GPCR ligand binding—CXCL8—breast cancer	0.000828	0.00227	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—MMP3—breast cancer	0.000826	0.00227	CbGpPWpGaD
Bisacodyl—Vomiting—Vinorelbine—breast cancer	0.000823	0.00155	CcSEcCtD
Bisacodyl—Dizziness—Thiotepa—breast cancer	0.000818	0.00154	CcSEcCtD
Bisacodyl—Headache—Vinorelbine—breast cancer	0.000811	0.00153	CcSEcCtD
Bisacodyl—Syncope—Docetaxel—breast cancer	0.000811	0.00153	CcSEcCtD
Bisacodyl—Carbinoxamine—CYP2D6—breast cancer	0.000809	0.198	CrCbGaD
Bisacodyl—GPR55—Signaling Pathways—DKK1—breast cancer	0.000808	0.00222	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—VEGFC—breast cancer	0.000802	0.0022	CbGpPWpGaD
Bisacodyl—Loss of consciousness—Docetaxel—breast cancer	0.000795	0.0015	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—JAG2—breast cancer	0.00079	0.00217	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Irinotecan—breast cancer	0.000787	0.00148	CcSEcCtD
Bisacodyl—Hypersensitivity—Mitoxantrone—breast cancer	0.000787	0.00148	CcSEcCtD
Bisacodyl—Vomiting—Thiotepa—breast cancer	0.000786	0.00148	CcSEcCtD
Bisacodyl—Syncope—Capecitabine—breast cancer	0.000785	0.00148	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—WNT1—breast cancer	0.000779	0.00214	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PLA2G4A—breast cancer	0.000777	0.00213	CbGpPWpGaD
Bisacodyl—Headache—Thiotepa—breast cancer	0.000775	0.00146	CcSEcCtD
Bisacodyl—Loss of consciousness—Capecitabine—breast cancer	0.00077	0.00145	CcSEcCtD
Bisacodyl—Nausea—Vinorelbine—breast cancer	0.000769	0.00145	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—CSF2—breast cancer	0.000768	0.00211	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Fluorouracil—breast cancer	0.000754	0.00142	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000752	0.00142	CcSEcCtD
Bisacodyl—Anaphylactic shock—Docetaxel—breast cancer	0.000738	0.00139	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—NOTCH4—breast cancer	0.000738	0.00202	CbGpPWpGaD
Bisacodyl—Nausea—Thiotepa—breast cancer	0.000735	0.00138	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—GZMB—breast cancer	0.000734	0.00201	CbGpPWpGaD
Bisacodyl—Diarrhoea—Irinotecan—breast cancer	0.000731	0.00138	CcSEcCtD
Bisacodyl—Diarrhoea—Mitoxantrone—breast cancer	0.000731	0.00138	CcSEcCtD
Bisacodyl—Shock—Docetaxel—breast cancer	0.000726	0.00137	CcSEcCtD
Bisacodyl—Nervous system disorder—Docetaxel—breast cancer	0.000724	0.00136	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Paclitaxel—breast cancer	0.000712	0.00134	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CXCL2—breast cancer	0.000712	0.00195	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—AGTR2—breast cancer	0.000712	0.00195	CbGpPWpGaD
Bisacodyl—Diarrhoea—Gemcitabine—breast cancer	0.000712	0.00134	CcSEcCtD
Bisacodyl—Dizziness—Irinotecan—breast cancer	0.000706	0.00133	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—BMP2—breast cancer	0.000704	0.00193	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PTHLH—breast cancer	0.000704	0.00193	CbGpPWpGaD
Bisacodyl—Shock—Capecitabine—breast cancer	0.000703	0.00132	CcSEcCtD
Bisacodyl—Nervous system disorder—Capecitabine—breast cancer	0.000701	0.00132	CcSEcCtD
Bisacodyl—Brompheniramine—CYP2D6—breast cancer	0.000701	0.172	CrCbGaD
Bisacodyl—Diarrhoea—Fluorouracil—breast cancer	0.0007	0.00132	CcSEcCtD
Bisacodyl—Carbinoxamine—CYP3A4—breast cancer	0.000694	0.17	CrCbGaD
Bisacodyl—Abdominal pain—Paclitaxel—breast cancer	0.000689	0.0013	CcSEcCtD
Bisacodyl—Chlorphenamine—CYP2D6—breast cancer	0.000688	0.169	CrCbGaD
Bisacodyl—GPR55—Signaling Pathways—EDNRB—breast cancer	0.000682	0.00187	CbGpPWpGaD
Bisacodyl—Vomiting—Mitoxantrone—breast cancer	0.000679	0.00128	CcSEcCtD
Bisacodyl—Vomiting—Irinotecan—breast cancer	0.000679	0.00128	CcSEcCtD
Bisacodyl—Immune system disorder—Methotrexate—breast cancer	0.000677	0.00127	CcSEcCtD
Bisacodyl—Dizziness—Fluorouracil—breast cancer	0.000676	0.00127	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PGR—breast cancer	0.000675	0.00185	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—THBS1—breast cancer	0.000672	0.00184	CbGpPWpGaD
Bisacodyl—Headache—Mitoxantrone—breast cancer	0.000669	0.00126	CcSEcCtD
Bisacodyl—Headache—Irinotecan—breast cancer	0.000669	0.00126	CcSEcCtD
Bisacodyl—Vomiting—Gemcitabine—breast cancer	0.000661	0.00124	CcSEcCtD
Bisacodyl—Malnutrition—Methotrexate—breast cancer	0.000652	0.00123	CcSEcCtD
Bisacodyl—Headache—Gemcitabine—breast cancer	0.000652	0.00123	CcSEcCtD
Bisacodyl—Vomiting—Fluorouracil—breast cancer	0.00065	0.00122	CcSEcCtD
Bisacodyl—Hypersensitivity—Paclitaxel—breast cancer	0.000642	0.00121	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—FLT1—breast cancer	0.000641	0.00176	CbGpPWpGaD
Bisacodyl—Headache—Fluorouracil—breast cancer	0.000641	0.00121	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—FGF3—breast cancer	0.000638	0.00175	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—SQSTM1—breast cancer	0.000638	0.00175	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Docetaxel—breast cancer	0.000637	0.0012	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—PIK3CG—breast cancer	0.000635	0.00174	CbGpPWpGaD
Bisacodyl—Nausea—Irinotecan—breast cancer	0.000634	0.00119	CcSEcCtD
Bisacodyl—Nausea—Mitoxantrone—breast cancer	0.000634	0.00119	CcSEcCtD
Bisacodyl—Immune system disorder—Epirubicin—breast cancer	0.000633	0.00119	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—JAG1—breast cancer	0.00063	0.00173	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PARP1—breast cancer	0.000628	0.00172	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—NOTCH3—breast cancer	0.000628	0.00172	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CALCA—breast cancer	0.00062	0.0017	CbGpPWpGaD
Bisacodyl—Nausea—Gemcitabine—breast cancer	0.000618	0.00116	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Capecitabine—breast cancer	0.000617	0.00116	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—RPS6—breast cancer	0.000613	0.00168	CbGpPWpGaD
Bisacodyl—Malnutrition—Epirubicin—breast cancer	0.00061	0.00115	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—FGF4—breast cancer	0.000608	0.00167	CbGpPWpGaD
Bisacodyl—Nausea—Fluorouracil—breast cancer	0.000608	0.00114	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CXCL12—breast cancer	0.000606	0.00166	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CXCR4—breast cancer	0.000606	0.00166	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Docetaxel—breast cancer	0.000604	0.00114	CcSEcCtD
Bisacodyl—Brompheniramine—CYP3A4—breast cancer	0.000601	0.147	CrCbGaD
Bisacodyl—Diarrhoea—Paclitaxel—breast cancer	0.000596	0.00112	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PAK1—breast cancer	0.000594	0.00163	CbGpPWpGaD
Bisacodyl—Chlorphenamine—CYP3A4—breast cancer	0.00059	0.145	CrCbGaD
Bisacodyl—Muscle spasms—Epirubicin—breast cancer	0.000587	0.0011	CcSEcCtD
Bisacodyl—Immune system disorder—Doxorubicin—breast cancer	0.000586	0.0011	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Capecitabine—breast cancer	0.000585	0.0011	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—TCF7L2—breast cancer	0.000584	0.0016	CbGpPWpGaD
Bisacodyl—Abdominal pain—Docetaxel—breast cancer	0.000584	0.0011	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—AKT2—breast cancer	0.000581	0.00159	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PIK3CG—breast cancer	0.000577	0.00158	CbGpPWpGaD
Bisacodyl—Dizziness—Paclitaxel—breast cancer	0.000576	0.00108	CcSEcCtD
Bisacodyl—Abdominal pain—Capecitabine—breast cancer	0.000565	0.00106	CcSEcCtD
Bisacodyl—Malnutrition—Doxorubicin—breast cancer	0.000565	0.00106	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—HSP90AA1—breast cancer	0.000563	0.00154	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—NOTCH2—breast cancer	0.000563	0.00154	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—PIK3CD—breast cancer	0.000558	0.00153	CbGpPWpGaD
Bisacodyl—Vomiting—Paclitaxel—breast cancer	0.000554	0.00104	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PRL—breast cancer	0.000548	0.0015	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—AGTR1—breast cancer	0.000548	0.0015	CbGpPWpGaD
Bisacodyl—Syncope—Epirubicin—breast cancer	0.000547	0.00103	CcSEcCtD
Bisacodyl—Headache—Paclitaxel—breast cancer	0.000546	0.00103	CcSEcCtD
Bisacodyl—Hypersensitivity—Docetaxel—breast cancer	0.000544	0.00102	CcSEcCtD
Bisacodyl—Muscle spasms—Doxorubicin—breast cancer	0.000543	0.00102	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—ADAM10—breast cancer	0.00054	0.00148	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—STK11—breast cancer	0.00054	0.00148	CbGpPWpGaD
Bisacodyl—Loss of consciousness—Epirubicin—breast cancer	0.000536	0.00101	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PLG—breast cancer	0.000534	0.00146	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Methotrexate—breast cancer	0.000532	0.001	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—AKT2—breast cancer	0.000528	0.00145	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Capecitabine—breast cancer	0.000527	0.000991	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—FGF10—breast cancer	0.000525	0.00144	CbGpPWpGaD
Bisacodyl—Nervous system disorder—Methotrexate—breast cancer	0.000522	0.000982	CcSEcCtD
Bisacodyl—Nausea—Paclitaxel—breast cancer	0.000517	0.000974	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—PIK3CD—breast cancer	0.000507	0.00139	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PDGFA—breast cancer	0.000507	0.00139	CbGpPWpGaD
Bisacodyl—Syncope—Doxorubicin—breast cancer	0.000506	0.000953	CcSEcCtD
Bisacodyl—Diarrhoea—Docetaxel—breast cancer	0.000505	0.000951	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—TGFBR2—breast cancer	0.000499	0.00137	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Epirubicin—breast cancer	0.000498	0.000937	CcSEcCtD
Bisacodyl—Loss of consciousness—Doxorubicin—breast cancer	0.000496	0.000934	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—ITPR1—breast cancer	0.000491	0.00135	CbGpPWpGaD
Bisacodyl—Shock—Epirubicin—breast cancer	0.00049	0.000922	CcSEcCtD
Bisacodyl—Diarrhoea—Capecitabine—breast cancer	0.000489	0.000921	CcSEcCtD
Bisacodyl—Nervous system disorder—Epirubicin—breast cancer	0.000488	0.000919	CcSEcCtD
Bisacodyl—Dizziness—Docetaxel—breast cancer	0.000488	0.000919	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—STAT5A—breast cancer	0.000488	0.00134	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—ERBB4—breast cancer	0.000488	0.00134	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MMP3—breast cancer	0.000488	0.00134	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—PIK3CB—breast cancer	0.000487	0.00134	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—SMAD4—breast cancer	0.000473	0.0013	CbGpPWpGaD
Bisacodyl—Dizziness—Capecitabine—breast cancer	0.000473	0.00089	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—IGF1R—breast cancer	0.00047	0.00129	CbGpPWpGaD
Bisacodyl—Vomiting—Docetaxel—breast cancer	0.000469	0.000884	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—CXCL8—breast cancer	0.000468	0.00128	CbGpPWpGaD
Bisacodyl—Headache—Docetaxel—breast cancer	0.000463	0.000871	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—HES1—breast cancer	0.000462	0.00127	CbGpPWpGaD
Bisacodyl—Anaphylactic shock—Doxorubicin—breast cancer	0.000461	0.000867	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Methotrexate—breast cancer	0.000459	0.000865	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PLA2G4A—breast cancer	0.000459	0.00126	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—NCOR1—breast cancer	0.000459	0.00126	CbGpPWpGaD
Bisacodyl—Vomiting—Capecitabine—breast cancer	0.000454	0.000855	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CSF2—breast cancer	0.000454	0.00124	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—FGF1—breast cancer	0.000454	0.00124	CbGpPWpGaD
Bisacodyl—Shock—Doxorubicin—breast cancer	0.000453	0.000853	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—RAF1—breast cancer	0.000453	0.00124	CbGpPWpGaD
Bisacodyl—Nervous system disorder—Doxorubicin—breast cancer	0.000452	0.00085	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—NRG1—breast cancer	0.00045	0.00124	CbGpPWpGaD
Bisacodyl—Headache—Capecitabine—breast cancer	0.000448	0.000843	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—H2AFX—breast cancer	0.000447	0.00123	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—IL2—breast cancer	0.000447	0.00123	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—E2F1—breast cancer	0.000444	0.00122	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—PIK3CB—breast cancer	0.000442	0.00121	CbGpPWpGaD
Bisacodyl—Nausea—Docetaxel—breast cancer	0.000439	0.000825	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Methotrexate—breast cancer	0.000435	0.000819	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Epirubicin—breast cancer	0.00043	0.000809	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—SPP1—breast cancer	0.000427	0.00117	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—CXCL8—breast cancer	0.000425	0.00117	CbGpPWpGaD
Bisacodyl—Nausea—Capecitabine—breast cancer	0.000425	0.000799	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—ERBB3—breast cancer	0.000422	0.00116	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—FGFR2—breast cancer	0.000421	0.00116	CbGpPWpGaD
Bisacodyl—Abdominal pain—Methotrexate—breast cancer	0.000421	0.000792	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Epirubicin—breast cancer	0.000407	0.000766	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—IL2—breast cancer	0.000406	0.00111	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—TERT—breast cancer	0.000404	0.00111	CbGpPWpGaD
Bisacodyl—Gastrointestinal disorder—Doxorubicin—breast cancer	0.000398	0.000749	CcSEcCtD
Bisacodyl—Abdominal pain—Epirubicin—breast cancer	0.000394	0.000741	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—FGFR1—breast cancer	0.000393	0.00108	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Methotrexate—breast cancer	0.000392	0.000738	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—HIF1A—breast cancer	0.000387	0.00106	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—LEP—breast cancer	0.000378	0.00104	CbGpPWpGaD
Bisacodyl—Gastrointestinal pain—Doxorubicin—breast cancer	0.000377	0.000709	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CAV1—breast cancer	0.000374	0.00103	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—KDR—breast cancer	0.00037	0.00101	CbGpPWpGaD
Bisacodyl—Hypersensitivity—Epirubicin—breast cancer	0.000367	0.000691	CcSEcCtD
Bisacodyl—Abdominal pain—Doxorubicin—breast cancer	0.000364	0.000686	CcSEcCtD
Bisacodyl—Diarrhoea—Methotrexate—breast cancer	0.000364	0.000685	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—ESR1—breast cancer	0.000361	0.000989	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—FN1—breast cancer	0.000356	0.000977	CbGpPWpGaD
Bisacodyl—Dizziness—Methotrexate—breast cancer	0.000352	0.000662	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—NFKBIA—breast cancer	0.000352	0.000965	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—NOTCH1—breast cancer	0.000348	0.000956	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PIK3CG—breast cancer	0.000341	0.000935	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—KIT—breast cancer	0.000341	0.000935	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—APC—breast cancer	0.000341	0.000935	CbGpPWpGaD
Bisacodyl—Diarrhoea—Epirubicin—breast cancer	0.000341	0.000641	CcSEcCtD
Bisacodyl—Hypersensitivity—Doxorubicin—breast cancer	0.000339	0.000639	CcSEcCtD
Bisacodyl—Vomiting—Methotrexate—breast cancer	0.000338	0.000637	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—EGF—breast cancer	0.000337	0.000924	CbGpPWpGaD
Bisacodyl—Headache—Methotrexate—breast cancer	0.000333	0.000627	CcSEcCtD
Bisacodyl—Dizziness—Epirubicin—breast cancer	0.000329	0.00062	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—MAPK3—breast cancer	0.000326	0.000895	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—BRAF—breast cancer	0.00032	0.000879	CbGpPWpGaD
Bisacodyl—Vomiting—Epirubicin—breast cancer	0.000317	0.000596	CcSEcCtD
Bisacodyl—Nausea—Methotrexate—breast cancer	0.000316	0.000595	CcSEcCtD
Bisacodyl—Diarrhoea—Doxorubicin—breast cancer	0.000315	0.000593	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—IGF1—breast cancer	0.000312	0.000856	CbGpPWpGaD
Bisacodyl—Headache—Epirubicin—breast cancer	0.000312	0.000587	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—AKT2—breast cancer	0.000312	0.000855	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—EGFR—breast cancer	0.00031	0.000852	CbGpPWpGaD
Bisacodyl—Dizziness—Doxorubicin—breast cancer	0.000305	0.000573	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—PIK3CD—breast cancer	0.0003	0.000822	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—PIK3CA—breast cancer	0.000297	0.000814	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—SERPINE1—breast cancer	0.000296	0.000813	CbGpPWpGaD
Bisacodyl—Nausea—Epirubicin—breast cancer	0.000296	0.000557	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—KRAS—breast cancer	0.000293	0.000804	CbGpPWpGaD
Bisacodyl—Vomiting—Doxorubicin—breast cancer	0.000293	0.000551	CcSEcCtD
Bisacodyl—Headache—Doxorubicin—breast cancer	0.000289	0.000543	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—NOS3—breast cancer	0.000283	0.000776	CbGpPWpGaD
Bisacodyl—Nausea—Doxorubicin—breast cancer	0.000274	0.000515	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—PIK3CA—breast cancer	0.000269	0.000739	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MDM2—breast cancer	0.000268	0.000736	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—RAF1—breast cancer	0.000267	0.000734	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—RELA—breast cancer	0.000266	0.00073	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—ERBB2—breast cancer	0.000265	0.000726	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MTOR—breast cancer	0.000261	0.000716	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PIK3CB—breast cancer	0.000261	0.000716	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CXCL8—breast cancer	0.000251	0.000688	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—HRAS—breast cancer	0.000249	0.000684	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CDKN1B—breast cancer	0.000245	0.000672	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—AKT1—breast cancer	0.000242	0.000665	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CASP3—breast cancer	0.00024	0.000659	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—IL2—breast cancer	0.00024	0.000658	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—IL6—breast cancer	0.000239	0.000654	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CCND1—breast cancer	0.000234	0.000641	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—JUN—breast cancer	0.000233	0.00064	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CTNNB1—breast cancer	0.000232	0.000635	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MMP9—breast cancer	0.000227	0.000622	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CDKN1A—breast cancer	0.000226	0.00062	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PTEN—breast cancer	0.000226	0.000619	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MAPK8—breast cancer	0.000221	0.000605	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—AKT1—breast cancer	0.00022	0.000604	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—SRC—breast cancer	0.000209	0.000574	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—VEGFA—breast cancer	0.000204	0.000559	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—STAT3—breast cancer	0.000202	0.000553	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MAPK3—breast cancer	0.000193	0.000529	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—MYC—breast cancer	0.000188	0.000514	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—TGFB1—breast cancer	0.000187	0.000513	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—EGFR—breast cancer	0.000183	0.000503	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—KRAS—breast cancer	0.000173	0.000475	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—PIK3CA—breast cancer	0.000159	0.000437	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—TP53—breast cancer	0.000154	0.000422	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—HRAS—breast cancer	0.000147	0.000404	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—IL6—breast cancer	0.000141	0.000387	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—AKT1—breast cancer	0.00013	0.000357	CbGpPWpGaD
